Stent Maker Stocks On Watch, Amgen Study Published: Healthcare Business Update

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Stocks of stent makers, such as Boston Scientific Corporation (NYSE:BSX), Abbott Laboratories (NYSE:ABT), and Medtronic (NYSE:MDT) could be on watch following a five-year study which indicated that bypass surgery is more effective than drug-coated stents in preventing heart attacks and deaths in diabetics with more than one diseased artery. However, bypass patients suffered more strokes.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Amgen (NASDAQ:AMGN) reports that Phase 2 studies of its investigational antibody AMG 145, in combination with statin therapy, resulted in a 56 percent reduction in low density lipoprotein cholesterol, which is called the “bad” cholesterol, in patients suffering from heterozygous familial hypercholesterolemia. This study has been published in Circulation and presented at the American Heart Association Scientific Sessions 2012.

Don’t Miss: Here’s How the Service Sector Is Growing.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business